Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

The analyst also pointed to a decision by an FDA advisory committee to reject Roche’s (OTCQX:RHHBY) lymphoma therapy Columvi, recently questioning the applicability of a trial that enrolled over ...

Summit Therapeutics (NASDAQ:SMMT) lost ~29% on Friday, marking its second-biggest intraday decline this year after the Miami, ...

“In my community practice, I’ve seen the potential of this Columvi combination to help patients start treatment quickly – providing lasting remissions and more time without ongoing therapy.

On Tuesday, May 20, 2025, the FDA's Oncologic Drug Advisory Committee (ODAC) voted 8-1 that results from the STARGLO trial (NCT04408638) of glofitamab-gxbm (Columvi) in relapsed/refractory diffuse ...

After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin ...

After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin ...

89% of patients whose cancer had fully responded at the end of treatment with Columvi in combination with chemotherapy were still alive and 82% showed no signs of cancer one year post-treatment 1 ...

After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin ...